290 reports of this reaction
3.5% of all CARMUSTINE reports
#3 most reported adverse reaction
MYELODYSPLASTIC SYNDROME is the #3 most commonly reported adverse reaction for CARMUSTINE, manufactured by Azurity Pharmaceuticals, Inc.. There are 290 FDA adverse event reports linking CARMUSTINE to MYELODYSPLASTIC SYNDROME. This represents approximately 3.5% of all 8,401 adverse event reports for this drug.
Patients taking CARMUSTINE who experience myelodysplastic syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELODYSPLASTIC SYNDROME is moderately reported among CARMUSTINE users, representing a notable but not dominant share of adverse events.
In addition to myelodysplastic syndrome, the following adverse reactions have been reported for CARMUSTINE:
The following drugs have also been linked to myelodysplastic syndrome in FDA adverse event reports:
MYELODYSPLASTIC SYNDROME has been reported as an adverse event in 290 FDA reports for CARMUSTINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELODYSPLASTIC SYNDROME accounts for approximately 3.5% of all adverse event reports for CARMUSTINE, making it one of the most commonly reported side effect.
If you experience myelodysplastic syndrome while taking CARMUSTINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.